缺血性脑卒中患者血浆1-磷酸鞘氨醇表达水平及风险列线图构建
Construction of Plasma Sphingosine 1-Phosphate Expression Level and Risk Nomogram in Patients with Ischemic Stroke
DOI: 10.12677/acm.2024.1451505, PDF,    科研立项经费支持
作者: 金保云*, 刘 源, 郝江杰, 李贝贝, 关红军#:牡丹江医学院公共卫生学院,黑龙江 牡丹江
关键词: 缺血性脑卒中生物标志物风险列线图Ischemic Stroke Biomarkers Risk Nomogram
摘要: 目的:探索缺血性脑卒中(Ischemic stroke, IS)患者血浆1-磷酸鞘氨醇(Sphingosine 1-phosphate, S1P)的水平变化并构建风险列线图模型。方法:选择2022年9月至2023年9月牡丹江红旗医院神经内科收治的113例IS患者为病例组。选取同期本院健康体检者146例为健康对照组。采用液相色谱联用质谱检测两组血浆S1P水平并绘ROC曲线,进行Logistic回归分析,并构建列线图风险模型。H-L拟合优度检验及校准曲线评价该列线图模型的预测效能。结果:IS组血浆S1P水平明显低于健康对照组为120.02 (97.90, 153.40) ng/mL比193.2 (158.77, 281.31) ng/mL,P < 0.001。血浆S1P水平诊断IS的截断值为150.82 ng/mL,曲线下面积为0.8441,灵敏度为78.8%,特异度为74.3%。二元Logistic回归分析表明,性别、BMI、血糖和高血压是IS发生的危险因素(P < 0.05)。模型ROC曲线下面积为0.974,95%CI为0.959~0.989;H-L拟合优度检验χ2 = 4.529,P = 0.873;模型预测IS患者发生的观测值和模型预测值基本一致,该模型具有较好的预测效能。结论:IS患者血浆S1P水平显著下降,S1P可能作为IS诊断的潜在生物标志物,为脑卒中诊治提供新的策略且构建的关于IS发生风险的列线图结果表明模型可以较好地预测IS发生的风险,用于指导临床实践。
Abstract: Objective: To explore the changes in plasma sphingosine 1-phosphate (S1P) levels of Ischemic stroke patients and to construct a risk nomogram model for ischemic stroke patients. Methods: 113 IS patients admitted to the Department of Neurology of Mudanjiang Red Flag Hospital from September 2022 to September 2023 were selected as the case group. A total of 146 healthy subjects were selected as the control group. The plasma S1P level of the two groups was detected by liquid chromatography combined with mass spectrometry and an ROC curve was drawn, Logistic regression analysis was performed, and the risk model of the nomogram was constructed. H-L goodness of fit test and calibration curve were used to evaluate the prediction efficiency of the nomogram. Results: Plasma S1P level in the IS group was significantly lower than that in the healthy control group (120.02 (97.90, 153.40) ng/mL vs. 193.2 (158.77, 281.31) ng/mL, P < 0.001). ROC curve showed that the cutoff value of plasma S1P level for the diagnosis of IS was 150.82 ng/mL, the area under the curve was 0.8441, the sensitivity was 78.8%, and the specificity was 74.3%. Multivariate Logistic regression analysis showed that gender, BMI, blood glucose, and hypertension were risk factors for the development of IS (P < 0.05). The area under the ROC curve predicted by the model was 0.974, and the 95%CI was 0.959~0.989. H-L goodness of fit test χ2 = 4.529, P = 0.873; the overall trend of the correction curve predicted by the model was consistent with the ideal curve, indicating that the model had good goodness of fit and good prediction efficiency. Conclusion: Plasma S1P levels are significantly decreased in patients with IS. S1P may be used as a potential biomarker for the diagnosis of IS, providing a new strategy for the diagnosis and treatment of stroke. The results of the constructed nomogram on the risk of IS development indicate that the model can better predict the risk of IS development, and can be used to guide clinical practice.
文章引用:金保云, 刘源, 郝江杰, 李贝贝, 关红军. 缺血性脑卒中患者血浆1-磷酸鞘氨醇表达水平及风险列线图构建[J]. 临床医学进展, 2024, 14(5): 901-910. https://doi.org/10.12677/acm.2024.1451505

参考文献

[1] Feigin, V.L., Nichols, E., Alam, T., et al. (2019) Global, Regional, and National Burden of Neurological Disorders, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18, 459-480. [Google Scholar] [CrossRef
[2] Feigin, V.L., Roth, G.A., Naghavi, M., et al. (2016) Global Burden of Stroke and Risk Factors in 188 Countries, during 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. The Lancet Neurology, 15, 913-924. [Google Scholar] [CrossRef
[3] Capirossi, C., Laiso, A., Renieri, L., et al. (2023) Epidemiology, Organization, Diagnosis and Treatment of Acute Ischemic Stroke. European Journal of Radiology Open, 11, Article ID: 100527. [Google Scholar] [CrossRef] [PubMed]
[4] Feigin, V.L., Stark, B.A., Johnson, C.O., et al. (2021) Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20, 795-820. [Google Scholar] [CrossRef
[5] 王淑娜, 缪朝玉. 脑卒中干细胞治疗机制及临床研究进展[J]. 中国药理学与毒理学杂志, 2019, 33(2): 81-92.
[6] Cartier, A. and Hla, T. (2019) Sphingosine 1-Phosphate: Lipid Signaling in Pathology and Therapy. Science, 366, eaar5551. [Google Scholar] [CrossRef] [PubMed]
[7] Aarthi, J.J., Darendeliler, M.A. and Pushparaj, P.N. (2011) Dissecting the Role of the S1P/S1PR Axis in Health and Disease. Journal of Dental Research, 90, 841-854. [Google Scholar] [CrossRef] [PubMed]
[8] Christoffersen, C., Obinata, H., Kumaraswamy, S.B., et al. (2011) Endothelium-Protective Sphingosine-1-Phosphate Provided by HDL-Associated Apolipoprotein M. Proceedings of the National Academy of Sciences, 108, 9613-9618. [Google Scholar] [CrossRef] [PubMed]
[9] Nitzsche, A., Poittevin, M., Benarab, A., et al. (2021) Endothelial S1P(1) Signaling Counteracts Infarct Expansion in Ischemic Stroke. Circulation Research, 128, 363-382. [Google Scholar] [CrossRef
[10] Venkataraman, K., Lee, Y.M., Michaud, J., et al. (2008) Vascular Endothelium as a Contributor of Plasma Sphingosine 1-Phosphate. Circulation Research, 102, 669-676. [Google Scholar] [CrossRef
[11] Argraves, K.M., Gazzolo, P.J., Groh, E.M., et al. (2008) High Density Lipoprotein-Associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function. Journal of Biological Chemistry, 283, 25074-25081. [Google Scholar] [CrossRef
[12] Brinkmann, V., Billich, A., Baumruker, T., et al. (2010) Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis. Nature Reviews Drug Discovery, 9, 883-897. [Google Scholar] [CrossRef] [PubMed]
[13] Zhu, X.Y., Ma, T.T., Li, Y., et al. (2023) Fingolimod Protects against Neurovascular Unit Injury in a Rat Model of Focal Cerebral Ischemia/Reperfusion Injury. Neural Regeneration Research, 18, 869-874. [Google Scholar] [CrossRef] [PubMed]
[14] Fu, Y., Zhang, N., Ren, L., et al. (2014) Impact of an Immune Modulator Fingolimod on Acute Ischemic Stroke. Proceedings of the National Academy of Sciences, 111, 18315-18320. [Google Scholar] [CrossRef] [PubMed]
[15] Kurano, M. and Yatomi, Y. (2018) Sphingosine 1-Phosphate and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 25, 16-26. [Google Scholar] [CrossRef
[16] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018 [J]. 中华神经科杂志, 2018, 51(9): 666-682.
[17] Babu, M.S., Kaul, S., Dadheech, S., et al. (2013) Serum Albumin Levels in Ischemic Stroke and Its Subtypes: Correlation with Clinical Outcome. Nutrition, 29, 872-875. [Google Scholar] [CrossRef] [PubMed]
[18] Bielewicz, J., Kurzepa, J., Czekajska-Chehab, E., et al. (2016) Worse Neurological State during Acute Ischemic Stroke Is Associated with a Decrease in Serum Albumin Levels. Journal of Molecular Neuroscience, 58, 493-496. [Google Scholar] [CrossRef] [PubMed]
[19] Dziedzic, T., Slowik, A. and Szczudlik, A. (2004) Serum Albumin Level as a Predictor of Ischemic Stroke Outcome. Stroke, 35, E156-E158. [Google Scholar] [CrossRef
[20] Chen, J., Fredrickson, V., Ding, Y., et al. (2013) Enhanced Neuroprotection by Local Intra-Arterial Infusion of Human Albumin Solution and Local Hypothermia. Stroke, 44, 260-262. [Google Scholar] [CrossRef
[21] Chen, H., Wang, J., Zhang, C., et al. (2022) Sphingosine 1-Phosphate Receptor, a New Therapeutic Direction in Different Diseases. Biomedicine & Pharmacotherapy, 153, Article ID: 113341. [Google Scholar] [CrossRef] [PubMed]
[22] McGinley, M.P. and Cohen, J.A. (2021). Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis and Other Conditions. The Lancet (London, England), 398, 1184-1194.[CrossRef
[23] Soltau, I., Mudersbach, E., Geissen, M., et al. (2016) Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans. PLOS ONE, 11, e0168302. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, J., Sugimoto, K., Cao, Y., et al. (2020) Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke. Frontiers in Neurology, 11, Article No. 985. [Google Scholar] [CrossRef] [PubMed]
[25] Cipolla, M.J., Liebeskind, D.S. and Chan, S.L. (2018) The Importance of Comorbidities in Ischemic Stroke: Impact of Hypertension on the Cerebral Circulation. Journal of Cerebral Blood Flow & Metabolism, 38, 2129-2149. [Google Scholar] [CrossRef
[26] Benjamin, E.J., Virani, S.S., Callaway, C.W., et al. (2021) Heart Disease and Stroke Statistics—2018 Update: A Report from the American Heart Association. Circulation, 137, e493. [Google Scholar] [CrossRef
[27] Tu, W.J., Wang, L.D. and Special Writing Group of China Stroke Surveillance Report (2023) China Stroke Surveillance Report 2021. Military Medical Research, 10, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, Z., Chen, Z., Zhang, L., et al. (2018) Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation, 137, 2344-2356.
[29] 庞艳敏, 田园梦, 井丽, 等. 辽宁省农村地区40岁及以上居民脑卒中复发现况及其相关危险因素分析[J]. 中国公共卫生, 2020, 36(3): 341-345.
[30] Baker, W.L., Marrs, J.C., Davis, L.E., et al. (2013) Key Articles and Guidelines in the Acute Management and Secondary Prevention of Ischemic Stroke. Pharmacotherapy, 33, E115-E142. [Google Scholar] [CrossRef] [PubMed]
[31] Mitchell, A.B., Cole, J.W., McArdle, P.F., et al. (2015) Obesity Increases Risk of Ischemic Stroke in Young Adults. Stroke, 46, 1690-1692. [Google Scholar] [CrossRef
[32] 臧艳静, 郑宏伟, 崔泽岩. 基于血清学指标的脑梗死患者预后列线图预测模型的建立与评估[J]. 中华老年心脑血管病杂志, 2022, 24(3): 277-280.